[HTML][HTML] The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
W Cao, S He, G Liu, H Schulz, K Emeterio, M Chan… - npj Vaccines, 2023 - nature.com
Recombinant vesicular stomatitis viruses (rVSVs) engineered to express heterologous viral
glycoproteins have proven to be remarkably effective vaccines. Indeed, rVSV-EBOV, which …
glycoproteins have proven to be remarkably effective vaccines. Indeed, rVSV-EBOV, which …
Functional characterization of AF-04, an afucosylated anti-MARV GP antibody
M Zhang, Y Zhang, H Wu, X Wang, H Zheng… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Marburg virus (MARV), one member of the Filoviridae family, cause sporadic outbreaks of
hemorrhagic fever with high mortality rates. No countermeasures are currently available for …
hemorrhagic fever with high mortality rates. No countermeasures are currently available for …
AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model
AD Rghei, W Cao, S He, JA Lopes… - The Journal of …, 2023 - academic.oup.com
Although there are no approved countermeasures available to prevent or treat disease
caused by Marburg virus (MARV), potently neutralizing monoclonal antibodies (mAbs) …
caused by Marburg virus (MARV), potently neutralizing monoclonal antibodies (mAbs) …
[HTML][HTML] The evolution and determinants of neutralization of potent head-binding antibodies against Ebola virus
Monoclonal antibodies against the Ebola virus (EBOV) surface glycoprotein are effective
treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope …
treatments for EBOV disease. Antibodies targeting the EBOV glycoprotein (GP) head epitope …
[HTML][HTML] Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the …
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP 1, 2) are the
standard of care for Ebola virus disease (EVD). Anti-GP 1, 2 mAbs targeting the stalk and …
standard of care for Ebola virus disease (EVD). Anti-GP 1, 2 mAbs targeting the stalk and …
A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies
FR Donnellan, V Rayaprolu, P Rijal, V O'Dowd… - bioRxiv, 2024 - biorxiv.org
Ebolavirus disease (EVD) is caused by multiple species of Ebolavirus. Monoclonal
antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic …
antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic …
[HTML][HTML] What Do Antibody Studies Tell Us about Viral Infections?
PA Ilinykh, K Huang - Pathogens, 2022 - mdpi.com
Humoral immunity is an important body defense system against virus infection and is
correlated to patient health status. Antibody response is a key factor in controlling virus …
correlated to patient health status. Antibody response is a key factor in controlling virus …